SAB Biotherapeutics

Bioscience gives back to industry partners working overtime

Bioscience workers putting in overtime + restaurants in need of business = Perfect chance to give back.

4 years ago

SAB joins forces with Pennsylvania company to develop COVID-19 therapeutic

Sioux Falls-based SAB Biotherapeutics is joining with global biotherapeutics leader CSL Behring to rapidly develop SAB-185, a COVID-19 therapeutic candidate on track for clinical evaluation by early summer.

4 years ago

SAB Biotherapeutics awarded up to $27 million to test rapid response antibodies

Sioux Falls-based SAB Biotherapeutics will receive up to $27 million from the U.S. Department of Defense to develop and test a rapid response antibody program .

4 years ago

SAB delays location at USD Discovery District to focus on COVID-19

SAB Biotherapeutics, a Sioux Falls immunotherapy company rapidly working to develop a therapeutic specific to COVID-19, announced it is delaying its planned development at the USD Discovery District for at least one year.

4 years ago

‘In the thick of it’: Sioux Falls company developing potential treatment for coronavirus

“It takes time, but we absolutely believe we are capable of producing a therapeutic response to this virus faster than anyone, and that’s what we are putting into place now.” As the world battles COVID-19, this Sioux Falls company is fighting back in a big way.

4 years ago

SAB Biotherapeutics to collaborate with global biotherapeutics leader

Sioux Falls-based SAB Biotherapeutics has entered into multiple collaboration and option agreements with Pennsylvania-based CSL Behring, a global biotherapeutics company that has more than 20,000 employees.

4 years ago

SAB adds to executive team with industry veteran

A biopharmaceutical industry veteran is piloting SAB Biotherapeutics’ immunotherapy products to market.

4 years ago

SAB announces $22 million in investment

SAB Biotherapeutics has raised $22 million in its Series A-2 round, which closed Dec. 15.

5 years ago

S.D. Equity Partners makes $1M investment in SAB

South Dakota Equity Partners has its first investment: A homegrown biotech company with big promise.

5 years ago

From inside SAB’s new ‘pharm,’ game-changing biopharmaceuticals are coming

“There has never been a platform, at least in my experience, that has been able to do so much so quickly.” The science being done at SAB Biotherapeutics could be huge, not just for South Dakota but for human disease. We got a rare look at where it all will start.

5 years ago

News Tip

Have a business news item to share with us?

Scroll to top